JP7089480B2 - Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 - Google Patents

Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 Download PDF

Info

Publication number
JP7089480B2
JP7089480B2 JP2018554765A JP2018554765A JP7089480B2 JP 7089480 B2 JP7089480 B2 JP 7089480B2 JP 2018554765 A JP2018554765 A JP 2018554765A JP 2018554765 A JP2018554765 A JP 2018554765A JP 7089480 B2 JP7089480 B2 JP 7089480B2
Authority
JP
Japan
Prior art keywords
acid
nad
derivatives
derivative
mitochondrial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018554765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514874A (ja
JP2019514874A5 (enExample
Inventor
デリンジャー，ライアン
ローンマス，トロイ
モリス，マーク
エリクソン，アロン
カシアー，ハディ
ミゴード，マリー，イー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of JP2019514874A publication Critical patent/JP2019514874A/ja
Publication of JP2019514874A5 publication Critical patent/JP2019514874A5/ja
Priority to JP2021117648A priority Critical patent/JP2021176871A/ja
Application granted granted Critical
Publication of JP7089480B2 publication Critical patent/JP7089480B2/ja
Priority to JP2022167877A priority patent/JP7493007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
JP2018554765A 2016-04-20 2017-04-20 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 Active JP7089480B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021117648A JP2021176871A (ja) 2016-04-20 2021-07-16 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用
JP2022167877A JP7493007B2 (ja) 2016-04-20 2022-10-19 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325264P 2016-04-20 2016-04-20
US62/325,264 2016-04-20
PCT/US2017/028673 WO2017184885A1 (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021117648A Division JP2021176871A (ja) 2016-04-20 2021-07-16 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用

Publications (3)

Publication Number Publication Date
JP2019514874A JP2019514874A (ja) 2019-06-06
JP2019514874A5 JP2019514874A5 (enExample) 2020-05-28
JP7089480B2 true JP7089480B2 (ja) 2022-06-22

Family

ID=60088650

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018554765A Active JP7089480B2 (ja) 2016-04-20 2017-04-20 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用
JP2021117648A Pending JP2021176871A (ja) 2016-04-20 2021-07-16 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用
JP2022167877A Active JP7493007B2 (ja) 2016-04-20 2022-10-19 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021117648A Pending JP2021176871A (ja) 2016-04-20 2021-07-16 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用
JP2022167877A Active JP7493007B2 (ja) 2016-04-20 2022-10-19 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用

Country Status (13)

Country Link
US (1) US10183036B2 (enExample)
EP (1) EP3445359B8 (enExample)
JP (3) JP7089480B2 (enExample)
KR (1) KR20190008246A (enExample)
CN (1) CN109640984A (enExample)
AU (2) AU2017254657A1 (enExample)
BR (1) BR112018071573A2 (enExample)
CA (1) CA3021571C (enExample)
ES (1) ES2948968T3 (enExample)
MX (1) MX393076B (enExample)
NZ (1) NZ747693A (enExample)
WO (1) WO2017184885A1 (enExample)
ZA (1) ZA201807736B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011788A1 (en) 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
KR102354784B1 (ko) 2015-08-05 2022-01-25 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CN110662542B (zh) 2016-11-11 2025-04-08 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、其磷酸化的类似物、其腺苷二核苷酸共轭物、以及其新颖结晶形式的有效且可规模化的合成
US11633421B2 (en) 2016-11-29 2023-04-25 University Of Iowa Research Foundation Use of NAD precursors for improving maternal health and/or offspring health
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
EP3558312A4 (en) 2016-12-21 2021-01-13 Newsouth Innovations Pty Limited METHODS FOR INCREASING VASCULAR DENSITY
WO2018191771A1 (en) * 2017-04-18 2018-10-25 Victor Chang Cardiac Research Institute Detection and treatment of congenital malformations
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US20210196742A1 (en) * 2018-05-22 2021-07-01 Jumpstart Fertility Pty Ltd Amino acid salts of nicotinic acid ribosides as anti-aging agents
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
BR112021016432A2 (pt) 2019-02-21 2021-11-09 Chromadex Inc Composição que compreende prills de cera, processo para produzir prills de cera, composição nutricional, alimento, bebida ou suplemento alimentar que compreende prills de cera, e composição que compreende microesferas encapsuladas
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
WO2020245190A1 (en) * 2019-06-05 2020-12-10 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for the treatment/prevention of liver disease
WO2020245187A1 (en) * 2019-06-05 2020-12-10 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for treating or preventing kidney disease
CA3141641A1 (en) * 2019-06-05 2020-12-10 Societe Des Produits Nestle S.A. Reduced nicotinamideribosides for treating/preventing skeletal muscle disease
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
US20230000888A1 (en) 2019-12-19 2023-01-05 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age related medical conditions
EP4117678A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
US20230138327A1 (en) * 2020-03-09 2023-05-04 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
WO2021180739A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of viral and bacterial infections
US20230119002A1 (en) * 2020-03-09 2023-04-20 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
CN114561342B (zh) * 2020-11-27 2024-12-20 西安交通大学医学院第一附属医院 Nad信号通路激动剂在体外胚胎培养中的应用
CN112716969B (zh) * 2021-01-15 2022-11-29 江苏恒正合生命科学有限公司 治疗阿尔茨海默症的组合物及其制备方法、应用
US20240245714A1 (en) * 2021-05-05 2024-07-25 Societe Des Produits Nestle S.A. Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+)
BR112023024712A2 (pt) 2021-05-27 2024-02-15 Metro Int Biotech Llc Sólidos cristalinos de mononucleotídeo de ácido nicotínico e ésteres dos mesmos e métodos de fabricação e uso
EP4313067A4 (en) * 2021-06-18 2024-12-18 Mitopower LLC TREATMENT OF IMMUNITY-RELATED DISORDERS, RENAL DISORDERS, LIVER DISORDERS, HEMOLYTIC DISORDERS AND OXIDATIVE STRESS-RELATED DISORDERS USING NRH, NARH AND THEIR REDUCED DERIVATIVES
WO2023076804A1 (en) * 2021-10-27 2023-05-04 Elysium Health Inc. Methods for treatment of menopausal syndromes
JP7111878B1 (ja) 2021-10-27 2022-08-02 旭化成ファーマ株式会社 ニコチンアミドモノヌクレオチドの製造方法
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter
JP2025505177A (ja) * 2022-02-04 2025-02-21 エリジウム ヘルス インコーポレーテッド リボースリンカーおよびその複合体
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101198A1 (en) 2002-05-30 2003-12-11 Albert Einstein College Of Medicine Of Zeshiva University Improved inhibitors of adp-ribosyl transferases, cyclases, and hydrolases
US20050042736A1 (en) 2003-08-22 2005-02-24 Ka-Yiu San High molar succinate yield bacteria by increasing the intracellular NADH availability
US20050267023A1 (en) 2002-08-09 2005-12-01 Sinclair David A Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2015066382A1 (en) 2013-10-30 2015-05-07 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
WO2015186114A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555675A1 (en) 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
DK1957086T3 (en) 2005-11-18 2018-06-06 Cornell Res Foundation Inc NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
US10280190B2 (en) * 2015-03-16 2019-05-07 Chromadex, Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions
WO2017011788A1 (en) 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
KR102354784B1 (ko) 2015-08-05 2022-01-25 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도
CA3021022C (en) * 2016-04-14 2024-04-23 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101198A1 (en) 2002-05-30 2003-12-11 Albert Einstein College Of Medicine Of Zeshiva University Improved inhibitors of adp-ribosyl transferases, cyclases, and hydrolases
US20050267023A1 (en) 2002-08-09 2005-12-01 Sinclair David A Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050042736A1 (en) 2003-08-22 2005-02-24 Ka-Yiu San High molar succinate yield bacteria by increasing the intracellular NADH availability
WO2015066382A1 (en) 2013-10-30 2015-05-07 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
WO2015186114A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
CN109640984A (zh) 2019-04-16
US20170304338A1 (en) 2017-10-26
BR112018071573A2 (pt) 2019-02-12
JP2019514874A (ja) 2019-06-06
CA3021571A1 (en) 2017-10-26
EP3445359B1 (en) 2023-06-07
AU2022221384C1 (en) 2023-08-03
EP3445359A1 (en) 2019-02-27
EP3445359B8 (en) 2023-09-06
MX2018012849A (es) 2019-08-29
AU2017254657A1 (en) 2018-11-15
US10183036B2 (en) 2019-01-22
JP2021176871A (ja) 2021-11-11
JP2023002685A (ja) 2023-01-10
MX393076B (es) 2025-03-24
ZA201807736B (en) 2020-05-27
WO2017184885A8 (en) 2023-08-24
NZ747693A (en) 2023-07-28
AU2022221384A1 (en) 2022-09-22
JP7493007B2 (ja) 2024-05-30
KR20190008246A (ko) 2019-01-23
ES2948968T3 (es) 2023-09-22
CA3021571C (en) 2023-01-03
EP3445359C0 (en) 2023-06-07
EP3445359A4 (en) 2019-12-25
WO2017184885A1 (en) 2017-10-26
AU2022221384B2 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
AU2022221384C1 (en) Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+ increasing precursors
AU2019214858B2 (en) Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CA3021022C (en) Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
JP6949002B6 (ja) ニコチンアミドモノヌクレオチド誘導体及びそれらの使用
TWI294875B (en) Phenylindoles for the treatment of hiv
JP2022522114A (ja) ニコチンアミドリボシド、ニコチン酸リボシド、還元ニコチニルリボシド化合物、及びニコチニルリボシド化合物誘導体の製剤への使用
JP2002523434A (ja) ミトコンドリア疾患の処置のための組成物および方法
JP2022501331A (ja) 少なくとも１つのグリシン又はその誘導体と、少なくとも１つのｎ−アセチルシステイン又はその誘導体と、少なくとも１つのニコチンアミドリボシド又はｎａｄ＋前駆体と、を使用する組成物及び方法
US20250082631A1 (en) Sleep improving agent
JP2015028010A (ja) フルオレン−アミド化合物およびその医薬用途
HK40004710A (en) Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors
KR20240051234A (ko) 심장질환용제 및 심장질환의 개선 방법
HK40076052A (en) Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
JP2020145939A (ja) アレルギー性鼻炎抑制用組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181227

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220610

R150 Certificate of patent or registration of utility model

Ref document number: 7089480

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250